Key facts
- It has raised $9.0M across 1 recorded rounds; the latest was Seed Round ($4.1M) in Aug 2022.
- Notable investors include MedTech Innovator, Mayo Clinic Platform, Popular.
- AccurKardia has filed 1 Form D with the SEC, most recently Jun 2023 ($4.1M sold to 41 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for AccurKardia
Funding rounds
1 roundsAbout AccurKardia
Developer of an ECG (Electrocardiogram)-based diagnostics software platform intended to enhance interpretation of electrocardiogram data for improved detection of cardiovascular and metabolic conditions. The company's platform offers automated ECG interpretation, cloud-based clinical integration, and AI (artificial intelligence) models for detecting electrolyte imbalance and structural heart disease, enabling healthcare providers and clinical teams to identify critical conditions earlier and improve patient care.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2019
- Employees
- 29
- Website
- accurkardia.com/
- Ownership
- Privately Held (backing)
AccurKardia doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AccurKardia shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AccurKardia in its N-PORT filings yet. We sweep new filings monthly.